Tetrathiomolybdate
- Generic Name
- Tetrathiomolybdate
- Drug Type
- Small Molecule
- Chemical Formula
- MoS4
- CAS Number
- 16330-92-0
- Unique Ingredient Identifier
- 91U3TGV99T
- Background
Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body.
- Indication
Investigated for use/treatment in liver disease and pulmonary fibrosis.
Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 23
- Registration Number
- NCT00189176
- Locations
- 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma
- Conditions
- Colorectal Carcinoma
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00176774
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma
- Conditions
- Esophageal Carcinoma
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 69
- Registration Number
- NCT00176800
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Tetrathiomolybdate in Hormone Refractory Prostate Cancer
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT00150995
- Locations
- 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
A Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris
- Conditions
- Psoriasis
- First Posted Date
- 2005-06-09
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 10
- Registration Number
- NCT00113542
- Locations
- 🇺🇸
University of Michigan Department of Dermatology, Ann Arbor, Michigan, United States
Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate
- Conditions
- Carcinoma, Hepatocellular
- First Posted Date
- 2000-10-05
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00006332
- Locations
- 🇺🇸
3912 Taubman Center, Ann Arbor, Michigan, United States
Study of Tetrathiomolybdate in Patients With Wilson Disease
- Conditions
- Wilson Disease
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2006-05-09
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 90
- Registration Number
- NCT00004339
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.